Bifidobacterium animalis ssp. lactis 420 Protects against Indomethacin-Induced Gastric Permeability in Rats

Table 4

Dose-responsiveness of Bifidobacterium lactis 420 against indomethacin-induced side effects.

Group^a	Quantities of permeability probes^b (mg/sample ± SD)		TDA^c (mm^2 ± SD)
	Sucrose	Lactulose : mannitol
Control	12.93 ± 4.08^d	0.87 ± 0.22	0.00 ± 0.00
NSAID	25.46 ± 8.94^d	0.85 ± 0.13	3.60 ± 5.13
Probiotic high dose	18.26 ± 7.09	0.79 ± 0.14	1.30 ± 2.68
Probiotic low dose	18.90 ± 6.53	0.87 ± 0.18	2.24 ± 3.15

^aThe treatment groups were control, indomethacin-challenged group (NSAID), and probiotic groups supplemented daily with 10¹⁰ colony forming units (high dose) or 10⁸ colony forming units (low dose) colony forming units of Bifidobacterium lactis 420 for seven days prior to indomethacin challenge.
^bSucrose measures gastric permeability, and the lactulose : mannitol-ratio reflects small-intestinal permeability.
^cTDA stands for total damaged area.
^dSignificant (ANOVA; P < 0.05) differences between treatment groups are denoted pair wise by superscript letters.